 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | STI-9199 / Sorrento
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - Feb 13, 2023
P2, N=0, Withdrawn, Sponsor: Sorrento Therapeutics, Inc.
N=24 --> 0 | Trial completion date: Oct 2022 --> Oct 2024 | Initiation date: Apr 2022 --> Apr 2023 | Completed --> Withdrawn | Trial primary completion date: Jun 2022 --> Jun 2024
- || STI-9199 / Sorrento
Trial completion, Trial completion date: Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - Jan 27, 2023
P2, N=24, Completed, Sponsor: Sorrento Therapeutics, Inc.
N=24 --> 0 | Trial completion date: Oct 2022 --> Oct 2024 | Initiation date: Apr 2022 --> Apr 2023 | Completed --> Withdrawn | Trial primary completion date: Jun 2022 --> Jun 2024 Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2022
- ||| STI-9199 / Sorrento
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - Aug 17, 2022
P2, N=24, Active, not recruiting, Sponsor: Sorrento Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2022 Not yet recruiting --> Active, not recruiting | N=700 --> 24 | Trial completion date: Jan 2023 --> Jul 2023 | Trial primary completion date: Jan 2023 --> Aug 2022
- ||||| STI-9199 / Sorrento
New P2 trial: Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - May 12, 2022
P2, N=700, Not yet recruiting, Sponsor: Sorrento Therapeutics, Inc.